Carolyn Bertozzi

Dr. Carolyn R.
Bertozzi is an Independent Director at Eli Lilly & Co., an Independent Director at OmniAb, Inc., an Independent Director at OmniAb Operations, Inc., a Member at Accademia Nazionale dei Lincei, a Member at American Academy of Arts & Sciences, a Member at American Chemical Society, a Member at American Society for Biochemistry & Molecular Biology, Inc., a Member at National Academy of Inventors, a Member at National Academy of Medicine (United States), a Member at National Academy of Sciences, a Member at The Royal Society, a Professor at Howard Hughes Medical Institute, Inc. and a Professor at Stanford University.
She is on the Board of Directors at Eli Lilly & Co., OmniAb, Inc., Stanford Chem-H, Grace Science Foundation, Xaira Therapeutics, Inc. and OmniAb Operations, Inc. Dr. Bertozzi was previously employed as a Co-Founder by TwoStep Therapeutics, Inc., an Independent Director by Alnylam Pharmaceuticals, Inc., a Co-Founder by Valora Therapeutics, Inc., a Founder by Lycia Therapeutics, Inc., a Co-Founder by Venn Biosciences Corp., a Chairman by Enable Biosciences, Inc., a Co-Founder by Palleon Pharmaceuticals, Inc., a Co-Founder by Redwood Bioscience, Inc., a Professor by University of California, Berkeley, a Co-Founder by Firefly Bio, Inc., and a Director-Molecular Foundry by Lawrence Berkeley National Laboratory.
She also served on the board at Catalent, Inc., Molecular Foundry and The Broad Institute, Inc. She received her undergraduate degree from Harvard University and a doctorate degree from the University of California, Berkeley.